Zhihai Wu

168 Dongping Street, Suzhou Industrial Park
Suzhou, 215123, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer.

IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: December 24, 2025

A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism.

A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism.

Journal: Molecular cancer therapeutics

Published: April 13, 2025

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.

Journal: Virology journal

Published: March 26, 2025

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.

Journal: Journal of hematology & oncology

Published: October 15, 2024

Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models.

Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models.

Journal: Cancer immunology, immunotherapy : CII

Published: January 08, 2024

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells.

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells.

Journal: Nature cancer

Published: October 25, 2022

Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy.

Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy.

Journal: International journal of biological macromolecules

Published: September 04, 2022

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.

Journal: Cancer immunology, immunotherapy : CII

Published: March 18, 2022

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.

Journal: Cell reports. Medicine

Published: December 08, 2021

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.

Journal: The Journal of clinical investigation

Published: September 13, 2021

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.

Journal: Oncoimmunology

Published: July 09, 2021

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity.

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity.

Journal: Nature communications

Published: November 26, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026